Novo Nordisk Sues Eli Lilly Over GLP-1 Drug Advertisements
Novo Nordisk has filed a lawsuit against Eli Lilly in New Jersey federal court, alleging misleading advertising claims about the efficacy of its GLP-1 weight loss drugs. The legal action could impact marketing strategies and investor sentiment within the pharmaceutical sector.
